Cell Therapeutics (NASDAQ:CTIC) plunged 25% after pricing a secondary offering of $60MM worth of convertible preferred notes. Originally announced at $40MM yesterday, the dilution is 50% worse than anticipated, converting to a price of $1.40 per share. The money will be used to launch lymphoma drug Pixuvri, and to fund studies of potential myelofibrosis pacritinib.

Fool.com analyst David Williamson labelled Cell Therapeutics a stay-away stock after its drug Opaxio received orphan drug status, and shares popped earlier this week. With shares up double digits, and management's strong history of dilution, it was less than a week before the pop was met with a cash raise. With less than $15MM on Cell Therapeutics' balance sheet, the funds were sorely needed -- but even with the company's improved financial footing, this is one stock that Dave just can't get excited about. For the full story and Dave's expert analysis, be sure to check out the video below.


While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.